Astellas Pharma Inc. (JOBS) Scraps Agreement with Neurosearch A/S on ACR16
TOKYO, March 3 (Reuters) - Astellas Pharma Inc, Japan's second-biggest drugmaker, said on Tuesday that it has scrapped its licensing agreement with a Neurosearch A/S unit on a drug to treat schizophrenia.